抗喘息薬およびCOPD治療薬の世界市場レポート 2025年

抗喘息薬およびCOPD治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.6％で1,070億1,000万米ドルに成長します。予測期間の成長は、電子タバコ/ベイプの人気の高まり、肥満レベルの上昇、テクノロジー、未診断人口の大規模なプール、COVID-19患者の治療への抗喘息薬およびCOPD治療薬の使用、脂肪の消費の増加に起因すると考えられます。予測期間における主な動向としては、喘息に対するプロバイオティクス医薬品の開発、事業ポートフォリオを拡大するための抗IL-5医薬品の開発、市場での地位確立と激しい競争の中での地位維持に注力するための革新的新製品の発売、バイオエレクトリック医薬品の開発への投資拡大、共同研究数の増加に注力、カスタマイズされた治療の提供、より良い結果を提供するための競合薬の開発、生物製剤の需要増加に対応するための生物製剤の開発などが挙げられます。

喫煙、座りがちなライフスタイル、不健康な食習慣などの変更可能な危険因子は、抗喘息薬およびCOPD治療薬市場の推進に大きく寄与しています。喫煙率は世界的に低下しているが、中国、インド、インドネシア、ナイジェリアなどの特定の開発途上国では喫煙率が上昇傾向にあります。例えば、インドネシアでは2025年までに2,400万人の喫煙者が増加し、ナイジェリアでは700万人の喫煙者が増加すると予測されています。さらに、中国は世界のたばこ消費量の40％以上を占めています。不健康な食生活、特に米国や欧州などの高所得国で一般的な脂肪や飽和脂肪酸の多量摂取は、喘息やCOPDに関連する危険因子の一因となっています。WHOのデータでは、先進国ではエネルギー摂取量の35％以上が脂肪からであるのに対し、低所得国では20％以下、低中所得国では25％以下です。

喘息性疾患の蔓延は、抗喘息薬およびCOPD治療薬市場の成長の原動力になると予想されます。気道の炎症と収縮を特徴とする慢性疾患である喘息は、症例数の増加傾向を示しており、これらの疾患を管理するための新しい薬剤の特定と開発を促しています。例えば、2022年4月の国民健康調査（NHIS）のデータによると、2020年の米国では18歳以下の小児の約42.7％、5歳以下の小児の52.9％が喘息であると報告されています。このような喘息患者の増加は、革新的な薬剤の継続的な開発を刺激し、抗喘息薬およびCOPD治療薬市場をさらに推進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界抗喘息薬およびCOPD治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の抗喘息薬およびCOPD治療薬市場：成長率分析
• 世界の抗喘息薬およびCOPD治療薬市場の実績：規模と成長, 2019-2024
• 世界の抗喘息薬およびCOPD治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界抗喘息薬およびCOPD治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗喘息薬およびCOPD治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 気管支拡張薬
• 抗炎症薬
• モノクローナル抗体
• 併用薬
• 世界の抗喘息薬およびCOPD治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 一般薬局
• オンライン小売業者
• 世界の抗喘息薬およびCOPD治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 喘息患者
• COPD患者
• 世界の抗喘息薬およびCOPD治療薬市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予防
• 治癒的
• 世界の抗喘息薬およびCOPD治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 吸入
• 静脈内
• 皮下
• 世界の抗喘息薬およびCOPD治療薬市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 5未満
• 2024年5月14日
• 15-60
• 60歳以上
• 世界の抗喘息薬およびCOPD治療薬市場気管支拡張薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 短時間作用型ベータ刺激薬（SABA）
• 長時間作用型ベータ刺激薬（LABA）
• 抗コリン剤（短時間作用型および長時間作用型）
• メチルキサンチン
• 世界の抗喘息薬およびCOPD治療薬市場抗炎症薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド（吸入および全身）
• ロイコトリエン修飾薬
• ホスホジエステラーゼ4阻害剤
• 世界の抗喘息薬およびCOPD治療薬市場、モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗IgE抗体
• 抗IL-5抗体
• 抗IL-4またはIL-13抗体
• 世界の抗喘息薬およびCOPD治療薬市場、複合薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 複合気管支拡張吸入器（LABA+LAMA）
• 吸入ステロイド薬+ 長時間作用型ベータ刺激薬（ICS+LABA）

第7章 地域別・国別分析

• 世界の抗喘息薬およびCOPD治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗喘息薬およびCOPD治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗喘息薬およびCOPD治療薬市場：競合情勢
• 抗喘息薬およびCOPD治療薬市場：企業プロファイル
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Chiesi Farmaceutici S.p.A.
• Teva Pharmaceutical Industries Limited
• Merck & Co. Inc.
• Sumitomo Dainippon Pharma Co. Ltd.
• China National Pharmaceutical Group Co. Ltd.（Sinopharm）
• Shanghai Acebright Pharmaceuticals Group Co. Ltd.
• Jiangsu Hengrui Medicine Co. Ltd
• Hanmi Pharmaceutical
• Cipla Limited
• Aurobindo Pharma Limited
• KYORIN Holdings Inc.
• Nichi-Iko Pharmaceutical Co. Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Daewoong Pharmaceutical Co. Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗喘息薬およびCOPD治療薬市場2029：新たな機会を提供する国
• 抗喘息薬およびCOPD治療薬市場2029：新たな機会を提供するセグメント
• 抗喘息薬およびCOPD治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anti-asthmatic and chronic obstructive pulmonary disease (COPD) drugs are medications designed to alleviate the frequency of acute attacks in conditions such as asthma, emphysema, chronic bronchitis, and nocturnal awakenings.

The primary classes of drugs in anti-asthmatics and COPD include bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. Bronchodilators stimulate the bronchi and bronchioles, reducing respiratory airway resistance and enhancing lung airflow. Various types of bronchodilators include anti-histamine drugs, long-acting B2-agonists (LABA), inhaled corticosteroids, short-acting muscarinic receptor antagonists (Samas), and other combinations of anti-asthmatics and COPD drugs. These medications are utilized by asthma and COPD patients and are distributed through diverse channels such as hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-commerce platforms.

The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market research report are one of a series of new reports from The Business Research Company that provides anti-asthmatics and chronic obstructive pulmonary disease (COPD) market statistics, including anti-asthmatics and chronic obstructive pulmonary disease (COPD) industry global market size, regional shares, competitors with an anti-asthmatics and chronic obstructive pulmonary disease (COPD) market share, detailed anti-asthmatics and chronic obstructive pulmonary disease (COPD) market segments, market trends and opportunities, and any further data you may need to thrive in the anti-asthmatics and chronic obstructive pulmonary disease (COPD) industry. These anti-asthmatics and chronic obstructive pulmonary disease (COPD) market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-asthmatics and COPD drugs market size has grown strongly in recent years. It will grow from $80.82 billion in 2024 to $86.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to include increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, geriatric population, emerging markets, new methods for drug discovery, and rise in healthcare expenditure.

The anti-asthmatics and COPD drugs market size is expected to see strong growth in the next few years. It will grow to $107.01 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to the increased popularity of e-cigarettes/ vaping, rising obesity levels, technology, a large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, and increasing consumption of fats. Major trends in the forecast period include developing probiotic drugs for asthma, developing anti-il-5 drugs to expand their business portfolio, launching new innovative products to focus on establishing their market position and sustaining their position among the intense competition in the market, investing more in developing bioelectric medicines, focus on increasing the number of collaborations, providing customized treatments, and developing combination drugs to offer better result, developing biologics to capitalize on the growing demand for biologics.

Modifiable risk factors such as smoking, sedentary lifestyles, and unhealthy dietary habits significantly contribute to driving the anti-asthmatics and copd drugs market. While smoking rates are declining globally, certain developing nations such as China, India, Indonesia, and Nigeria are witnessing an upward trend in smoking prevalence. For example, Indonesia is anticipated to see a rise of 24 million tobacco smokers by 2025, while Nigeria is expected to witness an increase of 7 million smokers. Additionally, China holds over 40% of global cigarette consumption. Unhealthy dietary practices, especially high consumption of fats and saturated fatty acids prevalent in high-income countries such as the USA and Europe, contribute to the risk factors associated with Asthma and COPD. WHO data highlights that in developed countries, over 35% of energy intake comes from fats, in contrast to less than 20% in low-income countries and below 25% in lower-middle-income countries.

The prevalence of asthmatic disorders is anticipated to be a driving force behind the growth of the anti-asthmatics and COPD drugs market. Asthma, a chronic condition characterized by airway inflammation and constriction, has shown an upward trend in cases, prompting the identification and development of new medications to manage these disorders. For example, based on data from the National Health Interview Survey (NHIS) in April 2022, approximately 42.7% of children aged 18 or younger and 52.9% of children under 5 years old were reported to have asthma in the United States in 2020. This rise in asthmatic cases is expected to stimulate the continuous development of innovative drugs, further propelling the anti-asthmatics and copd drugs market.

Numerous inhalers devoid of chlorofluorocarbons (CFCs) are presently accessible for managing asthma and chronic obstructive pulmonary disease (COPD). While these products might not be formally designated as direct replacements for CFC Metered Dose Inhalers, they can be considered beneficial medications for many patients, potentially eliminating the necessity for specific CFC Metered Dose Inhalers. The determination of official alternatives will be made by the FDA, employing criteria established via notice-and-comment rulemaking processes.

Major players within the anti-asthmatics and COPD drugs market are driving innovation with products such as the dose combination (FDC) drug, Indacaterol plus Mometasone, aiming to enhance their market position. This FDC medication, administered via the Breezhaler device, represents a once-daily treatment designed for ongoing asthma management in patients. Glenmark Pharmaceuticals, for instance, introduced the novel FDC drug named Indamet in India in June 2022. Available in three variations, Indamet maintains a consistent dose of 150 mcg of Indacaterol while varying Mometasone doses (80 mcg, 160 mcg, and 320 mcg strengths) to address uncontrollable asthma cases.

The trend toward combination therapies for asthma and COPD treatment is on the rise, showcasing greater efficacy in patient-reported outcomes (PROs) compared to monotherapies. Combinations such as short-acting beta-agonists (SABA) coupled with short-acting muscarinic antagonists (SAMA) have demonstrated superior effects on lung function when compared to individual medications. Similarly, the utilization of long-acting beta-agonists (LABA) paired with long-acting muscarinic antagonists (LAMA) has shown improved lung function in comparison to long-acting monotherapy bronchodilators.

Major companies operating in the anti-asthmatics and COPD drugs market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd, Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria

North America was the largest region in the anti-asthmatics and COPD drugs market in 2024. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and COPD drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-asthmatics and COPD drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The anti-asthmatic and chronic obstructive pulmonary disease market consists of corticosteroid, bronchodilator, fluticasone and salmeterol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Asthmatics And COPD Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-asthmatics and copd drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-asthmatics and copd drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-asthmatics and copd drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
• 2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
• 3) By End User: Asthma Patients, COPD Patients
• 4) By Therapy: Preventive, Curative
• 5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
• 6) By Age Group: Below 5, 5-14, 15-60, Above 60
• Subsegments:
• 1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs); Long-Acting Beta-Agonists (LABAs); Anticholinergics (Short-Acting And Long-Acting); Methylxanthines
• 2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic); Leukotriene Modifiers; Phosphodiesterase-4 Inhibitors
• 3) By Monoclonal Antibodies: Anti-IgE Antibodies; Anti-IL-5 Antibodies; Anti-IL-4 Or IL-13 Antibodies
• 4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA); Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
• Companies Mentioned: GlaxoSmithKline plc; AstraZeneca plc; Boehringer Ingelheim GmbH; F. Hoffmann-La Roche Ltd.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anti-Asthmatics And COPD Drugs Market Characteristics

3. Anti-Asthmatics And COPD Drugs Market Trends And Strategies

4. Anti-Asthmatics And COPD Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Anti-Asthmatics And COPD Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anti-Asthmatics And COPD Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anti-Asthmatics And COPD Drugs Market Growth Rate Analysis
• 5.4. Global Anti-Asthmatics And COPD Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anti-Asthmatics And COPD Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anti-Asthmatics And COPD Drugs Total Addressable Market (TAM)

6. Anti-Asthmatics And COPD Drugs Market Segmentation

• 6.1. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bronchodilators
• Anti-Inflammatory Drugs
• Monoclonal Antibodies
• Combination Drugs
• 6.2. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• General Pharmacies
• Online Retailers
• 6.3. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asthma Patients
• COPD Patients
• 6.4. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive
• Curative
• 6.5. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Inhaled
• Intravenous
• Subcutaneous
• 6.6. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Below 5
• 5/14/2024
• 15-60
• Above 60
• 6.7. Global Anti-Asthmatics And COPD Drugs Market, Sub-Segmentation Of Bronchodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Short-Acting Beta-Agonists (SABAs)
• Long-Acting Beta-Agonists (LABAs)
• Anticholinergics (Short-Acting And Long-Acting)
• Methylxanthines
• 6.8. Global Anti-Asthmatics And COPD Drugs Market, Sub-Segmentation Of Anti-Inflammatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids (Inhaled And Systemic)
• Leukotriene Modifiers
• Phosphodiesterase-4 Inhibitors
• 6.9. Global Anti-Asthmatics And COPD Drugs Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-IgE Antibodies
• Anti-IL-5 Antibodies
• Anti-IL-4 Or IL-13 Antibodies
• 6.10. Global Anti-Asthmatics And COPD Drugs Market, Sub-Segmentation Of Combination Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Bronchodilator Inhalers (LABA + LAMA)
• Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)

7. Anti-Asthmatics And COPD Drugs Market Regional And Country Analysis

• 7.1. Global Anti-Asthmatics And COPD Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anti-Asthmatics And COPD Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Asthmatics And COPD Drugs Market

• 8.1. Asia-Pacific Anti-Asthmatics And COPD Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Asthmatics And COPD Drugs Market

• 9.1. China Anti-Asthmatics And COPD Drugs Market Overview
• 9.2. China Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Asthmatics And COPD Drugs Market

• 10.1. India Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Asthmatics And COPD Drugs Market

• 11.1. Japan Anti-Asthmatics And COPD Drugs Market Overview
• 11.2. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Asthmatics And COPD Drugs Market

• 12.1. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Asthmatics And COPD Drugs Market

• 13.1. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Asthmatics And COPD Drugs Market

• 14.1. South Korea Anti-Asthmatics And COPD Drugs Market Overview
• 14.2. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Asthmatics And COPD Drugs Market

• 15.1. Western Europe Anti-Asthmatics And COPD Drugs Market Overview
• 15.2. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Asthmatics And COPD Drugs Market

• 16.1. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Asthmatics And COPD Drugs Market

• 17.1. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Asthmatics And COPD Drugs Market

• 18.1. France Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Asthmatics And COPD Drugs Market

• 19.1. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Asthmatics And COPD Drugs Market

• 20.1. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Asthmatics And COPD Drugs Market

• 21.1. Eastern Europe Anti-Asthmatics And COPD Drugs Market Overview
• 21.2. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Asthmatics And COPD Drugs Market

• 22.1. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Asthmatics And COPD Drugs Market

• 23.1. North America Anti-Asthmatics And COPD Drugs Market Overview
• 23.2. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Asthmatics And COPD Drugs Market

• 24.1. USA Anti-Asthmatics And COPD Drugs Market Overview
• 24.2. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Asthmatics And COPD Drugs Market

• 25.1. Canada Anti-Asthmatics And COPD Drugs Market Overview
• 25.2. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Asthmatics And COPD Drugs Market

• 26.1. South America Anti-Asthmatics And COPD Drugs Market Overview
• 26.2. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Asthmatics And COPD Drugs Market

• 27.1. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Asthmatics And COPD Drugs Market

• 28.1. Middle East Anti-Asthmatics And COPD Drugs Market Overview
• 28.2. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Asthmatics And COPD Drugs Market

• 29.1. Africa Anti-Asthmatics And COPD Drugs Market Overview
• 29.2. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Asthmatics And COPD Drugs Market Competitive Landscape And Company Profiles

• 30.1. Anti-Asthmatics And COPD Drugs Market Competitive Landscape
• 30.2. Anti-Asthmatics And COPD Drugs Market Company Profiles
  • 30.2.1. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Asthmatics And COPD Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Chiesi Farmaceutici S.p.A.
• 31.3. Teva Pharmaceutical Industries Limited
• 31.4. Merck & Co. Inc.
• 31.5. Sumitomo Dainippon Pharma Co. Ltd.
• 31.6. China National Pharmaceutical Group Co. Ltd. (Sinopharm)
• 31.7. Shanghai Acebright Pharmaceuticals Group Co. Ltd.
• 31.8. Jiangsu Hengrui Medicine Co. Ltd
• 31.9. Hanmi Pharmaceutical
• 31.10. Cipla Limited
• 31.11. Aurobindo Pharma Limited
• 31.12. KYORIN Holdings Inc.
• 31.13. Nichi-Iko Pharmaceutical Co. Ltd.
• 31.14. Otsuka Pharmaceutical Co. Ltd.
• 31.15. Daewoong Pharmaceutical Co. Ltd

32. Global Anti-Asthmatics And COPD Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Asthmatics And COPD Drugs Market

34. Recent Developments In The Anti-Asthmatics And COPD Drugs Market

35. Anti-Asthmatics And COPD Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Anti-Asthmatics And COPD Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anti-Asthmatics And COPD Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anti-Asthmatics And COPD Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer